Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis, Bristol To Share Zelmac; Novartis Opts For Partnership, Not Merger

Executive Summary

Novartis' agreement with Bristol Myers-Squibb to co-promote the irritable bowel syndrome treatment Zelmac (tegaserod) accomplishes one objective of the Swiss company's attempts to grow via a merger in the U.S.

You may also be interested in...



Novartis Merger Stance: Firm "Prefers" No Deal For At Least Two Years

Novartis would "prefer" to wait two or three years before its next large transaction so it can focus on upcoming product launches, CFO Raymund Breu told the J.P. Morgan CEO conference on building shareholder value April 26.

Novartis Merger Stance: Firm "Prefers" No Deal For At Least Two Years

Novartis would "prefer" to wait two or three years before its next large transaction so it can focus on upcoming product launches, CFO Raymund Breu told the J.P. Morgan CEO conference on building shareholder value April 26.

Novartis U.S. Rx Marketing Head Schofield Joins From Pharmacia

Novartis' efforts to reinvigorate its U.S. pharmaceuticals business in 2001 will be led by former Pharmacia VP-U.S. Sales Greg Schofield.

Related Content

UsernamePublicRestriction

Register

PS036783

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel